Peptide Schedule
CortexinSmall moleculeNo amino acid sequence. Icon reflects category theme only.Cortexin Dosage Calculator
Cortexin is a polypeptide bioregulator complex derived from the cerebral cortex of young cattle or pigs through acid extraction and purification.
5mcg · Daily
Summary: Add 2mL BAC water to your 5mg vial. Draw to 0.2 units on a U-100 syringe for a 5mcg dose. This vial will last 1000 doses.
Cycle Planner
Cortexin Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~1-3 hours (estimated, polypeptide complex)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Cortexin Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 5mg | Daily |
| Moderate | 10mg | Daily |
| Aggressive | 10mg | 2x Daily |
Note: Cortexin is a lyophilized polypeptide fraction extracted from the cerebral cortex of cattle or pigs. It has been approved in Russia since 1999 and is widely used across CIS countries for neurological conditions including ischemic stroke, traumatic brain injury, and cognitive impairment. Standard treatment courses are 10 days of daily intramuscular injections, repeated 2-4 times per year. Because Cortexin is a complex mixture of low-molecular-weight neuropeptides, amino acids, vitamins, and minerals rather than a single defined peptide, pharmacokinetic characterization of individual components is limited.
About Cortexin
Cortexin is a polypeptide bioregulator complex derived from the cerebral cortex of young cattle or pigs through acid extraction and purification. Developed at the Institute of Bioregulation and Gerontology in St. Petersburg, it belongs to the class of Khavinson peptide bioregulators — short-chain peptides believed to interact with specific gene promoter regions to modulate protein expression in target tissues. The preparation contains a standardized mixture of neuropeptides with molecular weights below 10 kDa, along with L-glycine, vitamins, and trace minerals. Cortexin was first registered in Russia in 1999 and has since become one of the most prescribed neuroprotective agents in the Russian Federation and neighboring countries. Clinical use spans a wide range of neurological conditions. In acute ischemic stroke, randomized controlled trials have demonstrated that adding Cortexin to standard therapy improves neurological deficit scores, accelerates functional recovery, and reduces 30-day mortality compared to placebo. For traumatic brain injury, studies show benefits in cognitive restoration, reduction of post-traumatic epilepsy risk, and improved Glasgow Outcome Scale scores at follow-up. In pediatric neurology, Cortexin has been studied for perinatal brain injury, delayed speech and psychomotor development, epilepsy, and attention deficit disorders, with multiple Russian clinical trials reporting positive outcomes. The proposed mechanism centers on tissue-specific gene regulation: the peptide fragments are thought to penetrate neuronal membranes and interact with chromatin, restoring optimal expression of neurotrophic factors such as BDNF and NGF while normalizing the balance between excitatory and inhibitory neurotransmission. Cortexin also exhibits antioxidant activity, reduces glutamate excitotoxicity, and stabilizes neuronal membrane potential under ischemic conditions. While the evidence base is large within Russian-language medical literature — with over 200 published studies — international peer-reviewed data remains limited, and no FDA-equivalent regulatory approval exists outside the CIS region.